Close

Anti-OR9Q2 (FLFTFFASI) TCR (BC7), Jurkat Cell Line (TCRJ-YF217)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The anti-OR9Q2 (FLFTFFASI) TCR Jurkat cell line is a stable cell line made from the anti-OR9Q2 TCR lentivirus. The recombinant Jurkat T cell was designed to predict the MOA of OR9Q2-TCR, measure the OR9Q2-TCR specificity and screen target cells expressing OR9Q2. And the product can be used to treat Cancer.

Specific Inquiry

  • Size:
  • Marker:
  • Positive rate:
  Add to Cart

Specifications

  • Cell Background
  • The Jurkat cell line was established from the peripheral blood of human T lymphocyte cells. Jurkat cells are used to study acute T cell leukemia, T cell signaling, and the expression of various chemokine receptors. Jurkat cells can produce interleukin 2, and are used in research involving the susceptibility of cancers to drugs and radiation.
  • Cell Type
  • T lymphocyte
  • Formulation
  • Containing ≥ 1 X 10*6 / vial frozen cells
  • Cell Purity
  • >95%
  • Cell Viability
  • >90%
  • Mycoplasma Testing
  • The cell line has been screened using the luciferase based mycoplasma detection kit to confirm the absence of mycoplasma species.
  • Applications
  • • Screen for activators or inhibitors of OR9Q2 signaling in a cellular context
    • Characterize the biological activity of OR9Q2 and its interactions with ligands
    • Predict the MOA of the TCR design
    • Screen and validate OR9Q2-expressing target cells
  • Storage
  • Frozen cells should be stored in a liquid nitrogen tank (-150°C~-190°C). Once reconstituted, the cells may be used for up to five days if properly stored at 2°C - 8°C in the buffer provided.
  • Handling Notes
  • Frozen cells should be thawed immediately upon receipt and grown according to handling procedure to ensure cell viability and proper assay performance.
    Note: Do not freeze the cells upon receipt as it may result in irreversible damage to the cell line.
    Disclaimer: We cannot guarantee cell viability if the cells are not thawed immediately upon receipt and grown according to handling procedure.
  • Warnings
  • Avoid multiple freeze/thaw cycles
  • Research Use Only
  • Our recombinant Jurkat cell are for research use only, not for diagnostic or therapeutic use.
  • Quality Control
  • Cultures are screened for the presence of bacteries, yeast, fungi and mycoplasma (DNA amplification). Growth media are also certified based on U.S. Public Health Service Guidelines.
  • Tumorgenicity
  • Positive (In vitro/vivo transformation assay)
  • Oncogenicity
  • Positive (In vitro soft agarose assay and life-time studies )
  • Sterility Testing
  • Creative Biolabs provides sterility testing in accordance with USP and EP regulations. All of our sterility testing is performed in an isolator or clean room environments. The cell line has been screened using the membrane filtration testing methods to confirm the absence of aerobic, anaerobic and fungi microorganisms.
  • Identity Testing
  • Identity testing is required for newly established cell lines. Isoenzyme analysis is used to confirm the identity of the species of a cell line. Alternative methods for identity testing include DNA fingerprinting, STR analysis and karyology.
  • Virological Safety Testing
  • A broad range of viruses is susceptible to affecting human cell lines. We can provide in vivo/vitro virus saftey assays by utilizing various animal systems. These viruses include: adventitious viruses, bovine viruses, human and simian viruses, porcine viruses, retrovirus and rodent viruses.
  • Genetic Stability Testing
  • We perform cell genetic stability studies under ICH guidelines. We
    can provide guidance on the appropriate testing program upon your requirements.

TCR Design

  • Target
  • OR9Q2
  • Introduction
  • Olfactory receptors interact with odorant molecules in the nose, to initiate a neuronal response that triggers the perception of a smell. The olfactory receptor proteins are members of a large family of G-protein-coupled receptors (GPCR) arising from single coding-exon genes. Olfactory receptors share a 7-transmembrane domain structure with many neurotransmitter and hormone receptors and are responsible for the recognition and G protein-mediated transduction of odorant signals. The olfactory receptor gene family is the largest in the genome. The nomenclature assigned to the olfactory receptor genes and proteins for this organism is independent of other organisms.
  • HLA
  • HLA-A*02:01
  • Common Name
  • OR9Q2
  • Target Species
  • Human
  • TCR Clone
  • BC7
  • TCR-Host Animal
  • Human
  • Vector Name
  • pCDTCR1
  • Vector length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • Targeting Diseases
  • Cancer
  • Epitope
  • FLFTFFASI
  • Format
  • Non-modified

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-OR9Q2 (FLFTFFASI) T Cell Receptor (BC7), Jurkat Cell Line (TCRJ-YF217). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.